Patents by Inventor Marc Labelle

Marc Labelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE IV inhibiting amides, compositions and methods of treatment
    Patent number: 6436965
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts and hydrates thereof are disclosed as useful for treating or preventing diseases and conditions mediated by PDE-IV. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 20, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Marc Labelle, Claudio Sturino, Nicolas Lachance, Dwight Macdonald
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • METHODS FOR INHIBITING BONE RESORPTION
    Publication number: 20020082287
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: October 13, 1999
    Publication date: June 27, 2002
    Inventors: SHUN-ICHI HARADA, GIDEON A. RODAN, MOHAMED MACHWATE, MARC LABELLE, KATHLEEN METTERS, ROBERT N. YOUNG
  • Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
    Publication number: 20020082266
    Abstract: This invention encompasses a method for the treatment or prevention of prostaglandin mediated diseases comprising administering to a mammalian patient a compound of formula I: 1
    Type: Application
    Filed: April 24, 2001
    Publication date: June 27, 2002
    Inventors: Michel Gallant, Nicolas Lachance, Marc Labelle, Robert Zamboni, Helene Juteau, Yves Gareau, Patrick Lacombe
  • Cyclopentanoindoles, compositions containing such compounds and methods of treatment
    Patent number: 6410583
    Abstract: Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: June 25, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Marc Labelle, Claudio Sturino, Bruno Roy, Carl Berthelette, Michael Boyd, Nicolas Lachance, John Scheigetz
  • PDE IV inhibiting amides, compositions and methods of treatment
    Publication number: 20020068756
    Abstract: Compounds represented by formula I: 1
    Type: Application
    Filed: March 1, 2001
    Publication date: June 6, 2002
    Inventors: Marc Labelle, Claudio Sturino, Nicolas Lachance, Dwight Macdonald
  • Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
    Patent number: 6369084
    Abstract: This invention encompasses the novel compounds of formula A, which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula A.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Patrick Lacombe, Marc Labelle, Rejean Ruel
  • Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
    Patent number: 6369082
    Abstract: This invention encompasses the novel compounds of formula A, which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Patrick Lacombe, Marc Labelle, Rejean Ruel
  • Methods for stimulating bone formation
    Publication number: 20020004495
    Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
    Type: Application
    Filed: July 3, 2001
    Publication date: January 10, 2002
    Inventors: Shun-Ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc Labelle, Kathleen Metters, Robert N. Young, Miron Weinreb
  • Prostaglandin D2 receptor antagonists
    Publication number: 20010047027
    Abstract: Certain tetrahydrocarbazole-1-acetic acid derivatives are potent and selective antagonists of the prostaglandin D2 receptor, and are therefore useful in the treatment of allergic conditions such as allergic rhinitis.
    Type: Application
    Filed: March 27, 2001
    Publication date: November 29, 2001
    Inventors: Marc Labelle, Claudio Sturino, Roy Bruno
  • Prostaglandin receptor ligands
    Publication number: 20010031766
    Abstract: Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed.
    Type: Application
    Filed: February 12, 2001
    Publication date: October 18, 2001
    Applicant: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Nicholas Lachance, Marc Labelle, Michel Gallant, Nathalie Chauret, Laird A. Trimble
  • Methods for inhibiting bone resorption
    Publication number: 20010018433
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: March 26, 2001
    Publication date: August 30, 2001
    Applicant: Merck & Co., Inc.
    Inventors: Shun-Ichi Harada, Mohamed Machwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • Biphenylene lactams as prostaglandin receptor ligands
    Patent number: 6277839
    Abstract: The present invention relates to biphenylene lactams of Formula II which are ligands at the prostaglandin receptors, as well as a method for treating prostaglandin mediated diseases comprising administration to a patient in need of such a treatment of a non-toxic therapeutically effective amount of compound of Formula II, and the like.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: August 21, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Joseph G. Atkinson, Marc Labelle, Patrick Lacombe, Rejean Ruel
  • COMBINATION PRODUCT AND METHODS OF USE
    Publication number: 20010012845
    Abstract: A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier. Methods of treatment are also disclosed wherein an E-type prostaglandin ligand and a COX-2 selective inhibiting compound are adminstered in an amount that is effective to treat or prevent an E-type prostaglandin and/or COX-2 mediated disease or condition.
    Type: Application
    Filed: October 22, 1999
    Publication date: August 9, 2001
    Inventors: CHI CHUNG CHAN, MARC LABELLE, KATHLEEN METTERS
  • Methods for inhibiting bone resorption
    Publication number: 20010012838
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: March 26, 2001
    Publication date: August 9, 2001
    Applicant: Merck & Co., Inc.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • METHODS FOR STIMULATING BONE FORMATION
    Publication number: 20010006980
    Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
    Type: Application
    Filed: October 13, 1999
    Publication date: July 5, 2001
    Inventors: SHUN-ICHI HARADA, MOHAMED MACHWATE, GIDEON A. RODAN, MARC LABELLE, KATHLEEN METTERS, ROBERT N. YOUNG, MIRON WEINREB
  • Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
    Patent number: 6242493
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts, hydrates and esters thereof, are disclosed. The compounds are useful for treating or preventing prostaglandin mediated diseases. Pharmaceutical compositions containing such compounds and methods of treatment are also included.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: June 5, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Gareau, Marc LaBelle, Helene Juteau, Michel Gallant, Nicolas LaChance, Michel Belley
  • Prostaglandin receptor ligands
    Patent number: 6211197
    Abstract: Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed. The compounds are represented by formula II: Ar1—W—Ar2—X—Q  II The compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: April 3, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Marc Labelle, Nicholas Lachance, Michel Gallant, Nathalie Chauret, Laird A. Trimble, Chun Li
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5856322
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: January 5, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Patrick Roy, Marc Labelle, Yi Bin Xiang, Daniel Guay
  • Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
    Patent number: 5834228
    Abstract: The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 10, 1998
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joseph W. Becker, Donald W. Nicholson, Jennifer Rotonda, Nancy A. Thornberry, Kimberly M. Fazil, Michel Gallant, Yves Gareau, Marc Labelle, Erin P. Peterson, Dita M. Rasper, Rejean Ruel, John P. Vaillancourt